

GAU2122



TECH CENTER 1600/2900

APR 02 2001

RECEIVED

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231

Typed or Printed Name	Matthew OH		
Signature		Date	12-21-2000
 TRANSMITTAL FORM	Attorney Docket	STAN-147	
	First Named Inventor	Mignot	
	Application Number	09/628,494	
	Filing Date	July 28, 2000	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
	title	Hypocretin (Orexin) Receptor in Regulation of Sleep and Treatment of Sleep Disorders	

RECEIVED


DEC 29 2000

Technology Center 2600

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Issue Fee Transmittal (with copy of PTOL-85B)	<input type="checkbox"/> Request for Refund
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> After Final Affidavits/declaration(s)	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition Routing Slip and Accompanying Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> To Convert a Provisional Application	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Information Disclosure Statement, 1449 and 100 references	<input type="checkbox"/> Power of Attorney	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Revocation	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Associate	<input type="checkbox"/> Return Postcard
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 (with copy of Notice to File Missing Parts)	<input type="checkbox"/> Change of Correspondence Address	
	<input type="checkbox"/> Terminal Disclaimer	
	<input type="checkbox"/> Small Entity Statement	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Carol L. Francis	Registration No.	36,513
Firm Name	BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	December 21, 2000		


RECEIVED

JAN 04 2001

Technology Center 2100

APR 02 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Matthew Ott		
Signature		Date	12-21-00
INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231		Attorney Docket	STAN-147
		First Named Inventor	Mignot
		Application Number	09/628494
		Filing Date	July 28, 2000
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Title	Hypocretin (Orexin) Receptor in Regulation of Sleep and Treatment of Sleep Disorders

RECEIVED

DEC 29 2000

Technology Center 2600



Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: December 21, 2000

By: 
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231
F:\FORMS\Word 2K forms\IDS - before 1st OA.doc

RECEIVED

JAN 04 2001

Technology Center 2100